Prof. Hua Keqin (华克勤) — Cervical Cancer Fertility Preservation & MDT | Red House Hospital Shanghai
A diagnosis of cervical cancer in a young woman raises two urgent and intertwined questions: Can the cancer be cured? And can the possibility of future pregnancy be preserved? For most patients, these questions have historically been treated as competing priorities — with oncological safety taking precedence and fertility being sacrificed. Prof. Hua Keqin (华克勤) at the Obstetrics & Gynecology Hospital of Fudan University (Red House Hospital) has built a program that refuses this trade-off, using a rigorous multidisciplinary approach to evaluate both dimensions simultaneously — and achieving outcomes that demonstrate the two goals are not mutually exclusive.
Prof. Hua's fertility preservation program achieves a 90% fertility preservation success rate and a post-surgery conception rate of 63.9% — outcomes that place her program among the most effective fertility-sparing cervical cancer programs in the world.
Specialty Focus
- Cervical cancer fertility preservation: MDT-based dual oncological and reproductive assessment
- Radical trachelectomy and fertility-sparing surgical techniques
- Minimally invasive gynecologic oncology surgery
- Ovarian cancer surgical management
- Endometrial cancer: surgical staging and fertility-sparing approaches
- Gynecologic cancer multidisciplinary treatment coordination
Academic & Clinical Titles
- Chief Physician & Professor, Department of Gynecologic Oncology, Obstetrics & Gynecology Hospital of Fudan University (Red House Hospital)
- Leader of specialized cervical cancer fertility preservation MDT program
- Fertility preservation success rate: 90%
- Post-surgery conception rate: 63.9%
The MDT Approach: Dual Oncological and Reproductive Assessment
The foundation of Prof. Hua Keqin's fertility preservation program is the multidisciplinary treatment (MDT) model — a structured framework in which every patient's case is evaluated simultaneously by specialists in gynecologic oncology, reproductive medicine, pathology, radiology, and medical oncology before any treatment decision is made.
This dual assessment addresses both dimensions of the patient's situation in parallel:
Oncological assessment: Is the tumor's stage, size, histological type, and pattern of spread compatible with fertility-sparing surgery? Can R0 resection be achieved while preserving the uterus? What is the risk of lymph node involvement, and how should it be managed? What adjuvant treatment, if any, will be required after surgery, and how will it affect fertility?
Reproductive assessment: What is the patient's baseline reproductive status? Are there pre-existing factors — ovarian reserve, uterine anatomy, partner fertility — that will affect the probability of successful conception after surgery? What surgical technique will best preserve the anatomical and functional prerequisites for pregnancy? What postoperative support — cervical cerclage, obstetric monitoring, assisted reproduction — will be needed?
By conducting these assessments simultaneously rather than sequentially, Prof. Hua's MDT ensures that the treatment plan is optimized for both oncological and reproductive outcomes from the outset — rather than attempting to salvage fertility after an oncologically-focused plan has already been implemented.
The Outcomes: 90% Preservation Success, 63.9% Conception Rate
The results of Prof. Hua's MDT-based approach are compelling:
90% fertility preservation success rate: Nine out of ten patients who enter Prof. Hua's fertility preservation program successfully undergo fertility-sparing surgery with oncologically adequate resection — meaning that the MDT assessment correctly identifies candidates for whom fertility preservation is both oncologically safe and technically feasible.
63.9% post-surgery conception rate: Among patients who attempt conception after fertility-sparing surgery, nearly two-thirds successfully achieve pregnancy. This figure reflects not only the technical quality of the surgical approach — which preserves uterine blood supply, cervical competence, and reproductive anatomy — but also the comprehensive postoperative reproductive support that Prof. Hua's program provides.
These outcomes are particularly meaningful when considered in context. Many patients who seek fertility-sparing cervical cancer surgery have been told by other physicians that fertility preservation is not possible, or have undergone fertility-sparing surgery elsewhere with suboptimal results. Prof. Hua's program offers a rigorous second assessment that may identify preservation options that were previously overlooked.
Who Is a Candidate for Fertility-Sparing Cervical Cancer Surgery?
Not all cervical cancer patients are candidates for fertility-sparing surgery. The generally accepted criteria include:
- Strong desire to preserve fertility
- Stage IA1 with lymphovascular space invasion, IA2, or IB1 (tumor ≤2 cm in most protocols; selected IB2 cases at specialized centers)
- Squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma histology (small cell neuroendocrine carcinoma is generally a contraindication)
- No evidence of lymph node metastasis on imaging
- No evidence of distant metastasis
- Adequate distance between the tumor and the internal cervical os to allow adequate surgical margins
Prof. Hua's MDT assessment evaluates each of these criteria rigorously, and her program's 90% success rate reflects the accuracy of this pre-surgical evaluation in identifying appropriate candidates. Patients who do not meet standard criteria may still be evaluated for modified approaches or alternative fertility-preservation strategies.
Postoperative Reproductive Support
Achieving pregnancy after radical trachelectomy requires more than a technically successful operation. Prof. Hua's program provides comprehensive postoperative reproductive support including:
- Cervical cerclage: Placement of a permanent cerclage at the time of trachelectomy to support the uterus and reduce the risk of second-trimester pregnancy loss
- Oncological surveillance: Regular follow-up to ensure early detection of any recurrence before conception is attempted
- Reproductive medicine coordination: Collaboration with reproductive medicine specialists for patients who require assisted conception (IVF, IUI) after surgery
- Obstetric monitoring: High-risk obstetric follow-up during pregnancy, with protocols for managing the increased risk of preterm labor associated with trachelectomy
Red House Hospital: Specialized Women's Health Excellence
The Obstetrics & Gynecology Hospital of Fudan University — Red House Hospital — is China's most specialized women's health institution, with over a century of history and a national reputation for gynecologic excellence. Its exclusive focus on women's health means that every aspect of the institutional infrastructure is optimized for gynecologic patients, and that the concentration of expertise in obstetrics, gynecology, reproductive medicine, and gynecologic oncology under one roof enables the kind of seamless multidisciplinary collaboration that Prof. Hua's MDT program requires.
For international patients, the hospital's specialized focus and Prof. Hua's program's track record provide a compelling combination: world-class oncological care delivered within an institutional environment uniquely suited to the needs of women with gynecologic cancers who wish to preserve their reproductive future.
Who Should Consider Consulting Prof. Hua Keqin
- Young women with early-stage cervical cancer who wish to preserve fertility and want a rigorous MDT-based assessment of their options
- Patients who have been told fertility preservation is not possible and want a second opinion from a specialized program
- Patients who have undergone fertility-sparing surgery elsewhere and have not achieved pregnancy, seeking evaluation for further options
- Patients with cervical cancer who want the most comprehensive simultaneous oncological and reproductive assessment available
- Patients with ovarian or endometrial cancer seeking expert gynecologic oncology evaluation
How CMCS Connects You with Prof. Hua Keqin
China Medical Concierge Shanghai (CMCS) facilitates access to Prof. Hua Keqin for international patients with cervical cancer seeking fertility preservation and other gynecologic malignancies. Our team manages the full coordination process — from remote case review and medical record translation to MDT submission, appointment scheduling, interpretation, and in-hospital support.
To begin, patients or their families are encouraged to share available medical records including pathology reports (with histological type, grade, and LVSI status), MRI pelvis (with tumor size measurement), CT chest/abdomen/pelvis, PET-CT if available, tumor markers, and prior treatment summaries. A baseline reproductive assessment (AMH, antral follicle count, partner semen analysis if applicable) is also helpful. Prof. Hua's MDT team can conduct an initial remote assessment before any travel to Shanghai is required.
CMCS provides end-to-end support including:
- Medical record translation (English, Arabic, French, and other languages)
- Remote pre-consultation MDT case submission
- Appointment coordination with Prof. Hua Keqin at Red House Hospital Shanghai
- On-site interpretation during consultations and procedures
- Reproductive medicine and assisted conception coordination
- Post-consultation summary and follow-up support
Contact CMCS to Connect with Prof. Hua Keqin
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
CMCS – China Medical Concierge Shanghai connects international patients with Shanghai's leading specialists. We are a health management company, not a hospital. All clinical decisions are made by the treating physician.
0 comments